DJIA 17,959.44 154.64 0.87%
NASDAQ 4,781.42 16.04 0.34%
S&P 500 2,078.54 7.89 0.38%
market minute promo

9.33 -0.13 (-1.37%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

HALO $9.33 -1.37%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $9.46
Previous Close $9.46
Daily Range $9.15 - $9.46
52-Week Range $6.88 - $18.18
Market Cap $1.2B
P/E Ratio -13.32
Dividend (Yield) $0.00 (0.0%)
Volume 1,174,268
Average Daily Volume 1,225,770
Current FY EPS -$0.66

Sector

Healthcare

Industry

Drugs

Halozyme Therapeutics, Inc. (HALO) Description

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets. Website: http://www.halozyme.com/

News & Commentary Rss Feed

Can Pfizer’s Cholesterol Drug Catch Up To The Competition?

Pfizer’s bococizumab remains in last place in the PCSK9 race. Will it arrive too late to make a meaningful impact on the market?

HALO Crosses Above Key Moving Average Level

Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst Blog

Relative Strength Alert For Halozyme Therapeutics

Halozyme to Present Preclinical Data on PEGPH20 at SABCS

Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annu

Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting

Halozyme Therapeutics - Buy The Drug Delivery Platform And Get A Cancer Drug For Free

Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2014 Results - Earnings Call Transcript

Halozyme Therapeutics Plummets On Q3 Losses

See More HALO News...

HALO's Top Competitors

HALO $9.33 (-1.37%)
Current stock: HALO
AMGN $164.53 (-3.31%)
Current stock: AMGN
GILD $92.90 (-14.34%)
Current stock: GILD
BIIB $352.29 (-2.32%)
Current stock: BIIB